At the time of this review, 24 therapeutics identified as tau-targeted by clinical trial sponsors have been tested in Phase 1 or later clinical trials, with 15 agents currently in active development based on publicly available data (see Table 2). Below, each potential pathogenic mechanism and relevant therapeutic approaches that are in or nearing human clinical trials are discussed.
